CA1204054A - Pharmaceutical compositions having an effect to control phagocytic functions - Google Patents

Pharmaceutical compositions having an effect to control phagocytic functions

Info

Publication number
CA1204054A
CA1204054A CA000441512A CA441512A CA1204054A CA 1204054 A CA1204054 A CA 1204054A CA 000441512 A CA000441512 A CA 000441512A CA 441512 A CA441512 A CA 441512A CA 1204054 A CA1204054 A CA 1204054A
Authority
CA
Canada
Prior art keywords
human
pepsin
enzyme
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000441512A
Other languages
English (en)
French (fr)
Inventor
Haruo Ohnishi
Hiroshi Kosuzume
Yasuo Suzuki
Ei Mochida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1204054A publication Critical patent/CA1204054A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000441512A 1982-11-20 1983-11-18 Pharmaceutical compositions having an effect to control phagocytic functions Expired CA1204054A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57203990A JPS5995221A (ja) 1982-11-20 1982-11-20 食細胞機能調節作用を有する医薬組成物
JP57-203990 1982-11-20

Publications (1)

Publication Number Publication Date
CA1204054A true CA1204054A (en) 1986-05-06

Family

ID=16482949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000441512A Expired CA1204054A (en) 1982-11-20 1983-11-18 Pharmaceutical compositions having an effect to control phagocytic functions

Country Status (11)

Country Link
US (1) US4534966A (de)
JP (1) JPS5995221A (de)
AU (1) AU552756B2 (de)
CA (1) CA1204054A (de)
CH (1) CH657050A5 (de)
DE (1) DE3341760A1 (de)
FR (1) FR2536281B1 (de)
GB (1) GB2132481B (de)
IT (1) IT1174799B (de)
NL (1) NL8303980A (de)
SE (1) SE460825B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067531B2 (en) 2004-11-12 2011-11-29 The Zhabilov Trust Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
US8309072B2 (en) * 2004-11-12 2012-11-13 The Zhabilov Trust Irreversibly-inactivated pepsinogen fragments for modulating immune function
WO2007041285A2 (en) * 2005-09-29 2007-04-12 Viral Genetics, Inc. Complexes of inactivated pepsin fraction and heat shock protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR59346E (fr) * 1949-06-09 1954-05-24 Valise roulante
US2930736A (en) * 1957-01-07 1960-03-29 Nat Drug Co Stabilized trypsin compositions containing partially hydrolyzed gelatin and method of making
FR2119872A1 (fr) * 1970-12-30 1972-08-11 Kuban Med I Im Krasnoi Armii Produit a base de pepsine,notamment pour le traitement des maladies s'accompagnant d'une insuffisance secretoire de l'estomac
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
CA1181005A (en) * 1981-02-10 1985-01-15 Haruo Ohnishi Therapeutic agent for treatment of allergic diseases, immune complex diseases and tumors
JPS6238329B1 (de) * 1982-02-09 1987-08-17 Mochida Pharm Co Ltd
WO1983004260A1 (en) * 1982-05-31 1983-12-08 Mochida Pharmaceutical Co., Ltd. Human leukocyte pepsin-like enzyme, and a therapeutic agent containing said enzyme as effective ingredient for treating allergic disorder, immune complex disease, and tumor

Also Published As

Publication number Publication date
DE3341760C2 (de) 1989-09-07
SE460825B (sv) 1989-11-27
GB2132481B (en) 1987-02-11
AU2155483A (en) 1984-05-24
CH657050A5 (de) 1986-08-15
JPH0261925B2 (de) 1990-12-21
GB8330810D0 (en) 1983-12-29
SE8306384D0 (sv) 1983-11-18
JPS5995221A (ja) 1984-06-01
DE3341760A1 (de) 1984-06-14
SE8306384L (sv) 1984-05-21
US4534966A (en) 1985-08-13
FR2536281A1 (fr) 1984-05-25
GB2132481A (en) 1984-07-11
AU552756B2 (en) 1986-06-19
NL8303980A (nl) 1984-06-18
FR2536281B1 (fr) 1989-05-12
IT1174799B (it) 1987-07-01
IT8349367A0 (it) 1983-11-21

Similar Documents

Publication Publication Date Title
Rockett et al. Possible role of nitric oxide in malarial immunosuppression
Snyderman et al. Biologic and Biochemical Activities of Continuous Macrophage Cell Lines P388D1 and J774.
AU624331B2 (en) A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier
Chua et al. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma
CA2182800A1 (en) Method of stimulating hematopoiesis with hemoglobin
US4916117A (en) Treatment of inflammation using alpha 1-antichymotrypsin
CA1204054A (en) Pharmaceutical compositions having an effect to control phagocytic functions
Meyers et al. Recombinant leukocyte A interferon for the treatment of serious viral infections after marrow transplant: a phase I study
KR20200126341A (ko) 분리된 미토콘드리아를 유효성분으로 포함하는 패혈증 또는 전신성 염증 반응 증후군 치료용 약학 조성물
AU763224B2 (en) Novel bioactivating substance
KR0128098B1 (ko) 항hiv제
IL146032A (en) Use of N-acetylcysteine for the preparation of appropriate intravenous drugs to prevent oxidative stress in dialysis patients
US5334395A (en) Method of treating an epstein-barr viral infection
Burnett et al. Pharmacological effects of various venoms on cutaneous capillary leakage
Huat et al. Biochemical characterization of an in-vitro murine megakaryocyte growth activity: megakaryocyte potentiator
JAMES H WILLIAMS et al. Inhibition of alveolar macrophages by pentoxifylline
AU598817B2 (en) Tumor necrosis factor alpha as treatment for infectious diseases
JPH04295500A (ja) 新規な巨核球増幅因子とその製法
EP0537722A2 (de) Polypeptide aus Schweineleber zur Behandlung viraler Infektionen
WO1994023730A1 (en) Method of treating hepatitis b infection
Zurbrick et al. Cultured bovine monocytes exhibit decreased release of superoxide anion and increased levels of lysosomal enzymes but do not secrete detectable lysozyme activity
Polmar Adenosine deaminase deficiency: enzyme replacement therapy and investigations of the biochemical basis of immunodeficiency
JPH0678243B2 (ja) 関節リウマチ治療剤
WO2002012444A2 (en) Amniotic apoptosis modulating substances
CA2297933A1 (en) A method to improve immune function

Legal Events

Date Code Title Description
MKEX Expiry